Cytotoxic antracenedione mitoxantrone has shown the efficacy as a disease-modifying therapy in patients with worsening and relapsing secondary multiple sclerosis (MS). However, the safety and its risk for developing malignancies has not been well established. The study published in the journal Neurology states that it may elevate the risk of leukemia and colorectal cancer in patients with MS.
The Cytotoxic antracenedione mitoxantrone has been in used for the treatment of relapsing-remitting, progressive relapsing, and secondary progressive multiple sclerosis (MS). In addition, it is the only approved disease-modifying agent for patients with secondary progressive MS without superimposed relapses. The drug is has a limited use as it was demonstrated to have occurrence of systolic cardiac dysfunction in about 12% patients treated with mitoxantrone and risk of acute myeloid leukemia (AML)…
